Benjamin F. Edwards & Company’s AstraZeneca AZN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.85M	Buy	18,277 +34	+0.2%	+$5.12K	0.05%	317
2024 Q1	$2.47M	Buy	18,243 +58	+0.3%	+$7.68K	0.04%	321
2023 Q4	$2.45M	Buy	18,185 +11,069	+156%	+$1.44M	0.05%	306
2023 Q3	$964K	Sell	7,116 -209	-3%	-$28.5K	0.04%	383
2023 Q2	$1.05M	Sell	7,325 -415	-5%	-$61.1K	0.04%	356
2023 Q1	$1.07M	Sell	7,740 -302	-4%	-$40.6K	0.05%	319
2022 Q4	$1.09M	Sell	8,042 -242	-3%	-$30.3K	0.05%	319
2022 Q3	$909K	Buy	8,284 +935	+13%	+$119K	0.05%	322
2022 Q2	$971K	Buy	7,349 +363	+5%	+$47.6K	0.05%	330
2022 Q1	$927K	Sell	6,986 -434	-6%	-$52K	0.04%	355
2021 Q4	$864K	Buy	7,420 +1,265	+21%	+$149K	0.04%	374
2021 Q3	$739K	Buy	6,155 +1,239	+25%	+$144K	0.04%	386
2021 Q2	$589K	Buy	4,916 +1,001	+26%	+$110K	0.03%	417
2021 Q1	$389K	Buy	3,915 +601	+18%	+$60.4K	0.02%	512
2020 Q4	$331K	Buy	3,314 +957	+41%	+$101K	0.02%	521
2020 Q3	$258K	Buy	2,357 +1,087	+86%	+$121K	0.02%	532
2020 Q2	$134K	Sell	1,270 -69	-5%	-$7.13K	0.01%	661
2020 Q1	$120K	Sell	1,339 -277	-17%	-$26.1K	0.01%	637
2019 Q4	$161K	Buy	1,616 +464	+40%	+$43.7K	0.01%	656
2019 Q3	$103K	Sell	1,152 -4,298	-79%	-$373K	0.01%	729
2019 Q2	$450K	Sell	5,450 -531	-9%	-$41.6K	0.04%	379
2019 Q1	$484K	Buy	5,981 +615	+11%	+$48.5K	0.04%	339
2018 Q4	$408K	Hold	5,366	–	–	0.04%	337
2018 Q3	$425K	Hold	5,366	–	–	0.04%	354
2018 Q2	$377K	Hold	5,366	–	–	0.04%	374
2018 Q1	$375K	Sell	5,366 -100	-2%	-$6.93K	0.04%	369
2017 Q4	$379K	Hold	5,466	–	–	0.04%	357
2017 Q3	$370K	Hold	5,466	–	–	0.04%	327
2017 Q2	$373K	Sell	5,466 -656	-11%	-$42.8K	0.05%	318
2017 Q1	$381K	Buy	6,122 +84	+1%	+$4.89K	0.06%	304
2016 Q4	$330K	Buy	6,038 +1,079	+22%	+$61.3K	0.05%	295
2016 Q3	$326K	Buy	4,959 +4,439	+854%	+$290K	0.06%	276
2016 Q2	$31K	Sell	520 -603	-54%	-$35K	0.01%	599
2016 Q1	$63K	Sell	1,123 -3,422	-75%	-$206K	0.01%	461
2015 Q4	$309K	Buy	4,545 +3,975	+697%	+$261K	0.07%	252
2015 Q3	$36K	Buy	570 +100	+21%	+$6.58K	0.01%	590
2015 Q2	$30K	Hold	470	–	–	0.01%	687
2015 Q1	$32K	Hold	470	–	–	0.01%	658
2014 Q4	$33K	Buy	470 +24	+5%	+$1.72K	0.01%	583
2014 Q3	$32K	Hold	446	–	–	0.01%	566
2014 Q2	$33K	Sell	446 -774	-63%	-$56K	0.01%	528
2014 Q1	$79K	Buy	1,220 +100	+9%	+$6.46K	0.02%	399
2013 Q4	$66K	Hold	1,120	–	–	0.02%	387
2013 Q3	$58K	Buy	1,120 +250	+29%	+$12.6K	0.02%	381
2013 Q2	$41K	Buy	+870	New	+$44.3K	0.02%	388

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Benjamin F. Edwards & Company's AZN Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its AstraZeneca (AZN) stake by 0.19% in Q2 2024, buying an estimated $5.12K and bringing the position to 18,277 shares worth $2.85M. The position accounts for 0.05% of the portfolio, ranked #317.

Benjamin F. Edwards & Company first reported a position in AZN in Q2 2013 and has held it in 45 quarters since. 1,212 funds tracked by Wall St. Rank hold AZN as of Q2 2024.

Benjamin F. Edwards & Company held 18,277 shares of AstraZeneca worth $2.85M as of Q2 2024.
Benjamin F. Edwards & Company bought 34 AstraZeneca shares in Q2 2024, an estimated $5.12K.
AstraZeneca made up 0.05% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #317 holding.
Benjamin F. Edwards & Company first reported a position in AstraZeneca in Q2 2013 and has held it in 45 quarters since.
1,212 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.